Hansoh pharma licenses cancer drug to Roche in $1.5bn deal

Hansoh Pharmaceutical Group’s wholly-owned subsidiaries, Shanghai Hansoh Biomedical Co., Ltd. and Changzhou Hansoh Pharmaceutical Co., Ltd., have entered into a license agreement with F. Hoffmann-La Roche Ltd for HS-20110, an investigational CDH17-targeting antibody-drug conjugate (ADC). This product is currently in global Phase I trials for colorectal cancer and other solid tumors.

Under the agreement, Hansoh grants Roche an exclusive worldwide license (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize HS-20110. Hansoh will receive an upfront payment of $80 million and is eligible for up to $1.45 billion in milestone payments, along with tiered royalties on future product sales.

The board believes this agreement serves the best interests of the company and its shareholders by maximizing the scientific and commercial value of the group's technology platforms.